Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Pivotal obesity trial | SURMOUNT-1: up to 22.5% weight loss at 72 weeks, 15mg (NEJM 2022) |
| Diabetes trial program | Separate program supporting Mounjaro approval |
| FDA approval | Approved as Mounjaro (T2D) and Zepbound (weight management) |
| Common trial side effects | GI: nausea, diarrhea, constipation, vomiting |
| Regulatory status | Prescription-only (approved use); unregulated when sold as research chemical |
What Tirzepatide Is
Tirzepatide is a synthetic peptide that activates two incretin hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). That dual mechanism distinguishes it from single-target GLP-1 drugs. It's FDA-approved under the brand name Mounjaro for type 2 diabetes and under the brand name Zepbound for chronic weight management, making it one of the most established medications in this drug class.
The Pivotal Trial: SURMOUNT-1
Tirzepatide's pivotal obesity trial, SURMOUNT-1, published in the New England Journal of Medicine in 2022, found weight loss of up to 22.5% at 72 weeks on the 15mg dose in adults with obesity or overweight and weight-related comorbidities. That result, from a large randomized, placebo-controlled trial, supported tirzepatide's FDA approval as Zepbound and is one of the most robust human evidence bases of any compound in this category. A separate trial program, evaluating glycemic control in type 2 diabetes, supported its earlier approval as Mounjaro.
Why this matters: tirzepatide's evidence picture is about as strong as peptide pharmacology gets: large randomized trials, dual regulatory approvals, and years of real-world prescribing experience on top of the trial data. It's one of the few compounds in this series where "has it been proven in humans" has a straightforwardly affirmative answer.
Trial Safety Signal
Tirzepatide's trials showed primarily gastrointestinal side effects: nausea, diarrhea, constipation, and vomiting, consistent with the pattern seen across incretin-based medications. These effects are most pronounced during dose escalation and tend to ease as the body adjusts to the medication, a pattern that has held up across its large trial population and subsequent real-world use.
Regulatory Status, By Source
Tirzepatide is FDA-approved as Mounjaro and Zepbound, manufactured by Eli Lilly under full pharmaceutical quality control and available by prescription through a licensed pharmacy. Material labeled "tirzepatide" is also sold by some suppliers as a research chemical, separate from the approved product. That research-chemical version has not been evaluated by the FDA for human use, regardless of how strong the trial evidence is for the approved pharmaceutical product; the trial data applies to the regulated drug, not to an unregulated vial sold outside that supply chain.
Bloodwork to Track
Tirzepatide's own trials tracked glucose, HbA1c, and lipid panel values given its incretin mechanism and metabolic effects. See the peptide bloodwork guide for what a baseline and follow-up panel typically includes.
Related Reading
For dosing and the full regulatory breakdown, see the Tirzepatide reference page. For how its evidence and approval status compare to an investigational triple agonist, see Retatrutide vs Tirzepatide. BioStackIQ's Rate My Stack and Build Protocol can help you think through where a compound like this fits into a broader stack.